Owned by the private equity ArchiMed since 2016, Fytexia Group, is a Life Science company that develops active nutrients for dietary supplements. 

Fytexia focuses on the research and scientific validation of bioactive molecule to provide functional ingredients for human health and well-being, targeting non-communicable diseases. Fytexia Group is the world expert in polyphenol and its subsidiary in Italy B Natural, the European leader in the extraction and refinement of brown propolis. Beyond Europe, Fytexia has also a presence in the United States and in Asia, serving its customers worldwide.  

ABFI, a division of the British FTSE 100 conglomerate Associated British Foods, has completed the acquisition of Fytexia following a process led by Potomac Transactions between September and December 2021.  ABFI is a global leader in specialty ingredients for the food, feed, pharmaceutical and industrial sectors. The acquisition of Fytexia will expand the product portfolio in the nutraceutical sector. 

 With offices in the U.S. and Europe, ArchiMed is a leading private equity firm dedicated to healthcare. ArchiMed manages more than €4 billion with an approach that combines operational, scientific, and financial expertise to help its companies accelerate growth organically and by acquisition.